

# IMMUNO SERIES

## Conference Schedule 2023



### IMMUNO UK

IN-PERSON

In-Person Congress  
& Exhibition

2-Day  
Event

- 300+ attendees & 70+ presentations
- A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools

March 2023  
London, UK

### Natural Killer Cell Symposium

Virtual Symposium

1-Day  
Event

- 200+ attendees & 15+ presentations
- Engage in scientific discussions on the latest tools and technologies for accelerated NK-based cellular immunotherapy development
- Benefit from exclusive insights from global influencers in NK-based cell therapy, addressing strategies for safety, quality control and off-target activity assessment, with the goal to fast-track to clinic

May 2023  
EDT (UTC-4)

### IMMUNO US

IN-PERSON

In-Person Congress  
& Exhibition

2-Day  
Event

- 200+ attendees & 40+ presentations
- Explore the latest developments in the fast-growing Immuno-Oncology field through this event, which brings together experts from global pharmaceutical organisations, leading biotechs and renowned academic institutions focussed on the development of immuno-oncology therapies and tools
- Co-located with Biomarkers US: In-Person 2023

October 2023  
San Diego, USA

### TUMOUR MICROENVIRONMENT

IN-PERSON

In-Person Congress  
& Exhibition

2-Day  
Event

- 200+ attendees and 30+ presentations
- Uncover how companies are furthering their understanding of the tumour microenvironment through the latest technologies, including spatial imaging and novel biomarkers
- Gain insights in emerging therapeutic opportunities through targeting the tumour microenvironment with immuno-oncology
- Co-located with Biomarker Analysis Europe: In-Person

November 2023  
Berlin, Germany



# Immuno UK: In-Person

March 2023 | London, UK

- 2-day Event
- In-Person Congress & Exhibition



A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

## Agenda at a Glance

### DAY ONE

#### Track 1: Discovery & Development: Cell & Combination Therapies

- Traditional Cell Therapies - T-Cells and NK Cells
- Non-Conventional Cell Therapies - Macrophages and TCRs
- Rationale of different combinations - IO agents combinations, as well as radiotherapy & chemotherapy

#### Track 2: Biomarkers & Precision Medicine in Immuno-Oncology

- Novel biomarkers in the Immuno-Oncology space
- Improving patient responses through biomarker development

#### Track 3: Autoimmunity Mechanisms & Novel Treatments

- Understanding regulation of autoimmunity
- Targeting the innate immune system

### DAY TWO

#### Track 1: Discovery & Development: Intratumoural Immunotherapies & Antibody Therapies

- Oncolytic and non-oncology viruses & agonists
- Delivering intratumoural immunotherapies for solid tumours
- Latest antibody-based approaches, including bispecifics

#### Track 2: Translational Development

- Development & delivery of personalised immunotherapy
- Genomic tools / Immunogenomics

#### Track 3: Preclinical & Clinical Development

- Translating animal models into human and clinically-relevant models for screening therapies
- Safety & toxicity considerations
- Clinical trial design & development

## Who will be there?


**300+ VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- Immuno-Oncology
- Cancer Immunology
- Oncology Biomarkers
- Cancer Vaccines
- Antibody Development
- Cell & Gene Therapy
- Microbiome for Immuno-Oncology
- Cancer Genetics
- Translational Immunology
- Preclinical & Clinical Oncology
- Combination Therapy

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- Target Identification & Validation
- Custom Antibodies
- Combination Screening Platforms
- Biomarker Service Platforms
- New Technologies
- Patient Selection & Stratification
- Personalised Medicine Services
- Sequencing
- Genomic Markers
- Single Cell Technologies
- Assay Development & Screening Models
- Diagnostics
- Tumour Microenvironment
- CROs
- Safety & Toxicity
- Data Management
- Cell Engineering

## Previous year's delegates in numbers:



# Natural Killer Cell Symposium

May 2023 | EDT (UTC-4)

- 1-day Event
- Virtual Symposium



Advance the development of NK-based cellular immunotherapies via optimised strategies for safe, persistent and targeted therapeutic action, ensuring fast-paced progression to the clinic.

## Agenda at a Glance

### Natural Killer Cells Symposium

#### Theme 1: Design & Development of NK-Based Therapies

- Increasing the safety and persistence of allogeneic NK therapies
- Genetic modification of NK cells to retarget and sustain anti-tumor activity
- In vitro approaches to accelerate off-target effect & toxicity research
- Leveraging mechanism of action to elicit stronger & safer therapeutic action
- Optimised analytical approaches tailored to NK-based therapies

#### Theme 2: Application of NK-Based Therapies

- Utilising the most effective strategy for solid tumors
- Harnessing NK cell memory for leukaemia immunotherapy
- Case studies of NK & CAR-NK clinical trials for haematological malignancies
- Strategies for combining NK cells with other agents

“There was a good mix of science and company/new technology being presented alongside company updates.”

- VICE PRESIDENT PROCESS DEVELOPMENT, ACHELLES THERAPEUTICS

## Benefits to Attending



**Engage in scientific discussions on the latest tools and technologies** for accelerated NK-based therapy development



**Gain insights into innovative technologies** for safety, quality control and off-target activity assessment of gene edited NK-based cell therapies





**Explore methods to fast-track to clinic** via robust analytics and toxicity research to facilitate informed strategic decisions on combination therapies and therapeutic applications

## How It Works

Oxford Global's online event platform has been designed and developed to offer an immersive conference experience, delivering all the benefits of a live in-person event at the touch of a button.

Our online events are delivered through Swapcard, our market-leading and highly interactive digital event platform. Alongside the live programme, it has a variety of other features to maximise your event experience, including AI-assisted match-making with other delegates, additional resource such as white papers, exhibitor pages allowing you to connect with leading solution providers and a host of On-Demand content.

Our conferences are designed to maximise interactivity. Each event features panel discussions facilitated by our expert speakers, and you can also join us for our live Q&As where a panel of speakers are ready to answer any questions you may have. The platform further increases your interactions with other attendees by making it simple to connect, chat, share files and more.





# Immuno US: In-Person

October 2023 | San Diego, USA

- 2-day Event
- In-Person Congress & Exhibition



Explore the latest developments in the fast-growing Immuno-Oncology field through the Advances in Immuno-Oncology US event, which brings together experts from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions all focussed on the development of immuno-oncology therapies and tools.

The event is co-located with our Biomarkers US: In-Person 2023 providing an in-depth look at the latest biomarker and translational data across multiple therapeutic areas.

## Agenda at a Glance

### Immuno US: In-Person

#### Day One

##### Track 1: Discovery & Development: Cell Therapies & Antibody Approaches

- Traditional Cell Therapies - T-Cells and NK Cells
- Non-Conventional Cell Therapies - Macrophages and TCRs
- Latest antibody-based approaches, including bispecifics

##### Track 2: Biomarkers in Immuno-Oncology

- Novel biomarkers in the Immuno-Oncology space
- Improving patient responses through biomarker development
- Diagnostic tools within I-O, including liquid biopsies for precise treatments

#### Day Two

##### Track 1: Discovery & Development: Intratumoural Immunotherapies & Combination Strategies

- Oncolytic and non-oncology viruses and agonists
- Delivering intratumoural immunotherapies for solid tumours
- Rational of different combinations, including combination of IO agents as well as radiotherapy & chemotherapy

##### Track 2: Translational & Preclinical Development

- Assay development, including pharmacodynamic assays
- Translating animal models into human and clinically-relevant models for screening therapies
- Safety & Toxicity considerations

## Who will be there?


**200+ VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- |                       |                        |                             |
|-----------------------|------------------------|-----------------------------|
| • Immuno-Oncology     | • Strategic Partnering | • Agonist Antibodies        |
| • Target Discovery    | • Cancer Genetics      | • Clinical Oncology         |
| • Oncology Biomarkers | • Antibody Engineering | • Clinical Trial Management |
| • Cancer Vaccines     | • Oncolytic Viruses    | • Immunotherapy             |

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- |                          |                           |                         |
|--------------------------|---------------------------|-------------------------|
| • Clinical Development   | • Antibody Engineering    | • Preclinical Discovery |
| • Strategic Partnerships | • Clinical Management     | • Cell Engineering      |
| • Cell-based Assays      | • Diagnostics Development | • In Vitro Screening    |

**Previous year's delegates in numbers**  
(incl. delegates from the co-located Biomarkers Series US):



# Tumour Microenvironment: In-Person

November 2023 | Berlin, Germany

- **2-day Event**
- **In-Person Congress & Exhibition**



Learn about recent advances in tumour microenvironment research at the basic, translational and clinical application levels, with exploration of the latest biomarker and spatial technologies to better understand the tumour microenvironment, alongside emerging therapeutic opportunities to target immune cells.

## Agenda at a Glance

### Tumor Microenvironment: In-Person

#### Understanding the Tumour Microenvironment

- Tools for better understanding of the tumour microenvironment
- Novel technologies for interrogating the microenvironment:
  - » Spatial biology
  - » Immunofluorescence
  - » Imaging
  - » Novel biomarkers
- 3D modelling of the tumour microenvironment for mechanistic understanding
- Computational approaches to analyse the microenvironment
- Strategies to phenotype immune cells

#### Targeting Immune Cells in the Tumour Microenvironment

- Enhanced identification & validation of therapeutically significant targets
- Exploiting metabolic symbiosis & reprogramming the tumour microenvironment to overcome resistance
- Penetration of solid tumours: T cell targets and strategies
- Acceleration of novel myeloid-directed therapies to the clinic
- Strategies to modulate tumour-resident myeloid populations

#### Harnessing the Tumour Microenvironment

- Promising modalities for cancer immunotherapy:
  - » Employing cytokines to modulate the tumor stroma
  - » Immune checkpoint inhibitors to kickstart immunity in cold tumors
  - » Monoclonal antibodies targeting the immunosuppressive tumor microenvironment
- Case studies of therapeutic targeting for leukaemia and lymphoma
- Combination therapies to drive improved clinical outcomes
- Strategies to address challenges in solid tumors

## Who will be there?

**200+ VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- Biomarker Development
- Immuno-Oncology
- Computational Biology
- Tissue Analysis
- Tumour Microenvironment
- Cancer Metabolism

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- Spatial Biology
- AI & Machine Learning
- Biomarker Development
- Imaging
- Immunofluorescence
- Tissue Assays